Sanofi Beats Back Apotex Generic In Uroxatral MDL
A federal judge overseeing the multidistrict litigation arising from Sanofi-Aventis SA's prostate drug Uroxatral has held that the patent covering the treatment was valid and infringed by Apotex Inc.'s proposed generic...To view the full article, register now.
Already a subscriber? Click here to view full article